利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.021 秒)

    Immunogenic Compositions and Vaccines in the Treatment and Prevention of Infections
    1.
    发明公开
    Immunogenic Compositions and Vaccines in the Treatment and Prevention of Infections 审中-公开

    公开(公告)号：US20230201326A1

    公开(公告)日：2023-06-29

    申请号：US17985296

    申请日：2022-11-11

    申请人： Longhorn Vaccines and Diagnostics, LLC

    发明人： Gerald W. Fischer ,  Clara J. Sei

    IPC分类号： A61K39/116 ,  A61K39/04 ,  A61K47/64

    CPC分类号： A61K39/116 ,  A61K39/04 ,  A61K47/646

    摘要： The invention is directed to portions of proteins of gram-positive bacteria, gram-negative, acid-fast bacteria (Mycobacteria, Staphylococcus) and/or virus (SARS-COV-2, Influenza), and antibodies reactive against these portions that can be formulated as immunogenic compositions and vaccines for the treatment and prevention of a microbial and/or viral infections. Preferably, compositions of the invention contain one or more portions of selected microbial and/or viral proteins that, upon administration to a subject, generate an effective cellular and/or humoral immune response, modulate immunity and a cytokine response. Effective responses involve an increased generation of antibodies that enhance immunity against an infection and promote an enhanced a phagocytic response. Monoclonal antibodies produced against these peptides enhance phagocytosis and killing of bacteria, viruses, and other microbes by phagocytic cells, and enhance clearance from the blood.

    Monoclonal Antibodies that Modulate Immunity to MTB and Enhance Immune Clearance
    2.
    发明申请
    Monoclonal Antibodies that Modulate Immunity to MTB and Enhance Immune Clearance 审中-公开
    调节免疫MTB和增强免疫清除的单克隆抗体

    公开(公告)号：US20170008954A1

    公开(公告)日：2017-01-12

    申请号：US15275813

    申请日：2016-09-26

    申请人： Longhorn Vaccines and Diagnostics, LLC

    发明人： Gerald W. Fischer ,  Luke T. Daum ,  Richard F. Schuman ,  Clara J. Sei

    IPC分类号： C07K16/12 ,  A61K45/06 ,  A61K39/04 ,  A61K39/40

    CPC分类号： C07K16/1289 ,  A61K39/04 ,  A61K39/12 ,  A61K39/40 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/521 ,  A61K2039/522 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/70 ,  C07K14/35 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/31 ,  C12N2760/16134

    摘要： The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response. Monoclonal antibodies produced by the non-naturally occurring antigens enhance phagocytosis and killing of mycobacteria by phagocytic cells, enhance clearance of MTB from the blood and modulate immunity and cytokine responses.

    摘要翻译： 本发明涉及用于在感染病原体之前或之后，特别是MTB刺激，增强或调节患者的免疫系统的组合物和方法。 本发明的组合物含有非天然存在的抗原，其产生对MTB抗原特异性反应的MTB和/或抗体的有效细胞和/或体液免疫应答。 由本发明的疫苗产生的免疫系统的更大活性增加了对MTB感染提供更大和/或延长响应的记忆T细胞的产生。 反应涉及增加一代抗体，增强对MTB感染的免疫力并促进增强的吞噬反应。 由非天然存在的抗原产生的单克隆抗体通过吞噬细胞增强吞噬和杀伤分枝杆菌，增强MTB从血液中的清除并调节免疫和细胞因子反应。

    Antibodies that modulate immunity to drug resistant and latent MTB infections
    4.
    发明授权
    Antibodies that modulate immunity to drug resistant and latent MTB infections 有权

    公开(公告)号：US10787504B2

    公开(公告)日：2020-09-29

    申请号：US16530520

    申请日：2019-08-02

    申请人： Longhorn Vaccines and Diagnostics, LLC

    发明人： Gerald W. Fischer ,  Luke T. Daum ,  Richard F. Schuman ,  Clara J. Sei

    IPC分类号： C07K16/00 ,  C07K16/12 ,  A61K45/06 ,  A61K39/40 ,  A61K39/04 ,  A61P31/06 ,  A61K39/12 ,  A61P31/16 ,  A61K39/00

    摘要： The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response. Monoclonal antibodies produced by the non-naturally occurring antigens enhance phagocytosis and killing of mycobacteria by phagocytic cells, enhance clearance of MTB from the blood and modulate immunity and cytokine responses.

    Modulation of Immunity to Drug Resistant and Latent MTB
    8.
    发明申请
    Modulation of Immunity to Drug Resistant and Latent MTB 有权

    公开(公告)号：US20220088166A1

    公开(公告)日：2022-03-24

    申请号：US17022893

    申请日：2020-09-16

    申请人： Longhorn Vaccines and Diagnostics, LLC

    发明人： Gerald W. Fischer ,  Luke T. Daum ,  Richard F. Schuman ,  Clara J. Sei

    IPC分类号： A61K39/04 ,  A61K45/06 ,  A61P31/06

    摘要： The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response. Monoclonal antibodies produced by the non-naturally occurring antigens enhance phagocytosis and killing of mycobacteria by phagocytic cells, enhance clearance of MTB from the blood and modulate immunity and cytokine responses.

    Antibodies that modulate immunity to drug resistant and latent MTB infections
    9.
    发明授权
    Antibodies that modulate immunity to drug resistant and latent MTB infections 有权

    公开(公告)号：US10370437B2

    公开(公告)日：2019-08-06

    申请号：US15850208

    申请日：2017-12-21

    申请人： Longhorn Vaccines and Diagnostics, LLC

    发明人： Gerald W. Fischer ,  Luke T. Daum ,  Richard F. Schuman ,  Clara J. Sei

    IPC分类号： A61K39/02 ,  C07K16/12 ,  A61K45/06 ,  A61K39/40 ,  A61K39/04 ,  A61P31/06 ,  A61K39/00

    摘要： The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response. Monoclonal antibodies produced by the non-naturally occurring antigens enhance phagocytosis and killing of mycobacteria by phagocytic cells, enhance clearance of MTB from the blood and modulate immunity and cytokine responses.